Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.
Pieber TR, Bode B, Mertens A, Cho YM, Christiansen E, Hertz CL, Wallenstein SOR, Buse JB, PIONEER 7 investigators.
Lancet Diabetes Endocrinol. 2019 Jul;7(7):528-539.
http://doi.org/10.1016/S2213-8587(19)30194-9

Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range.
Diabetes Care. 2019 Aug;42(8):1593-1603.
http://doi.org/10.2337/dci19-0028

Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial.
Miras AD, Pérez-Pevida B, Aldhwayan M, Kamocka A, McGlone ER, Al-Najim W, et al.
Lancet Diabetes Endocrinol. 2019 Jul;7(7):549-559.
http://doi.org/10.1016/S2213-8587(19)30157-3

Intensive Glucose Control in Patients with Type 2 Diabetes — 15-Year Follow-up
Reaven, P,  Emanuele N, Wiitala, N et al  for the VADT Investigators
N Engl J Med 2019; 380:2215-2224
10.1056/NEJMoa1806802